← Leaderboards
Bonnie W Ramsey
University Of Washington
$21,623,756
Attributed
$25,955,747
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$39,861,439 · 14
By mechanism
U01$20,223,958 · 3
P30$16,022,066 · 7
R01$3,603,823 · 2
M01$11,592 · 2
Top collaborators
- Everett P Greenberg9 shared
- Julie R Park5 shared
- Drucy Borowitz4 shared
- Pradeep Singh4 shared
Most similar at University Of Washington
Same institution · by research overlap
- Margaret Rosenfeld$6,120,159
- Hans D Ochs$9,229,500
- Kathleen Jessica Ramos$3,387,316
- Donald Leslie Chi$10,851,003
- Richard A Kronmal$28,990,646
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisChildResearch PersonnelBaseLinkCollaborationsProgramsClinical TrialsInfectionClinical ResearchTranslational ResearchSpecimenInstitutionLeadAffectGrantNational Institute Of Diabetes And Digestive And Kidney DiseasesPseudomonas AeruginosaSafetyFundingDatabasesDesignAreaCystic Fibrosis Transmembrane Conductance Regulator
Grant awards (59)
Administrative Core$152,614
P30 · FY2024 · DK · contact PI
Administrative Core$152,614
P30 · FY2023 · DK · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,395,617
U01 · FY2022 · TR
Administrative Core$152,614
P30 · FY2022 · DK · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,390,827
U01 · FY2021 · TR
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,214,759
P30 · FY2021 · DK · contact PI
Administrative Core$152,614
P30 · FY2021 · DK · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,386,496
U01 · FY2020 · TR
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,230,099
P30 · FY2020 · DK · contact PI
Administrative Core$166,264
P30 · FY2020 · DK · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,416,172
U01 · FY2019 · TR
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis$1,212,966
P30 · FY2019 · DK · contact PI
Administrative Core$134,718
P30 · FY2019 · DK · contact PI
Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders$1,478,374
U01 · FY2018 · TR
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis$1,212,966
P30 · FY2018 · DK · contact PI
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis$1,213,020
P30 · FY2017 · DK · contact PI
OPTIMIZE - CCC - Lead Application$910,954
U01 · FY2017 · HL · contact PI
OPTIMIZE - CCC - Lead Application$1,219,588
U01 · FY2016 · HL · contact PI
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis$1,212,966
P30 · FY2016 · DK · contact PI
Administrative Core$119,011
P30 · FY2016 · DK · contact PI
OPTIMIZE - CCC - Lead Application$1,550,633
U01 · FY2015 · HL · contact PI
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis$1,225,520
P30 · FY2015 · DK · contact PI
Baby Observational and Nutritional Study of Cystic Fibrosis$413,603
R01 · FY2015 · DK · contact PI
Administrative Core$128,748
P30 · FY2015 · DK · contact PI
OPTIMIZE - CCC - Lead Application$1,678,874
U01 · FY2014 · HL · contact PI
Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis$1,131,845
P30 · FY2014 · DK · contact PI
Baby Observational and Nutritional Study of Cystic Fibrosis$456,406
R01 · FY2014 · DK · contact PI
OPTIMIZE - CCC - Lead Application$87,501
U01 · FY2014 · HL · contact PI
OPTIMIZE - CCC - Lead Application$1,159,052
U01 · FY2013 · HL · contact PI
Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis$1,068,748
P30 · FY2013 · DK · contact PI
Baby Observational and Nutritional Study of Cystic Fibrosis$397,273
R01 · FY2013 · DK · contact PI
Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis$1,136,517
P30 · FY2012 · DK · contact PI
Baby Observational and Nutritional Study of Cystic Fibrosis$329,214
R01 · FY2012 · DK · contact PI
Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis$964,191
P30 · FY2011 · DK · contact PI
Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis$982,095
P30 · FY2010 · DK · contact PI
Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis$100,000
P30 · FY2010 · DK · contact PI
Early Antipseudomonal Therapy in Cystic Fibrosis$1,155,162
U01 · FY2008 · HL · contact PI
Core--Human Applications$142,980
P30 · FY2008 · DK · contact PI
Early Antipseudomonal Therapy in Cystic Fibrosis$1,234,448
U01 · FY2007 · HL · contact PI
Core--Human Applications$128,444
P30 · FY2007 · DK · contact PI
Early Antipseudomonal Therapy in Cystic Fibrosis$1,361,462
U01 · FY2006 · HL · contact PI
Core--Human Applications$169,621
P30 · FY2006 · DK · contact PI
Early Antipseudomonal Therapy in Cystic Fibrosis$1,388,177
U01 · FY2005 · HL
Core--Human Applications$169,621
P30 · FY2005 · DK
Early Antipseudomonal Therapy in Cystic Fibrosis$1,410,621
U01 · FY2004 · HL
Core--Human Applications$182,521
P30 · FY2004 · DK
INHALED TOBRAMYCIN IN YOUNG CYSTIC FIBROSIS PATIENTS$702,749
R01 · FY2003 · DK
PILOT AND FEASIBILITY PROGRAM$0
P30 · FY2002 · DK
CORE--HUMAN APPLICATIONS FACILITY$0
P30 · FY2002 · DK
INHALED TOBRAMYCIN IN YOUNG CYSTIC FIBROSIS PATIENTS$680,303
R01 · FY2001 · DK
PILOT AND FEASIBILITY PROGRAM$0
P30 · FY2001 · DK
CORE--HUMAN APPLICATIONS FACILITY$0
P30 · FY2001 · DK
INHALED TOBRAMYCIN IN YOUNG CYSTIC FIBROSIS PATIENTS$624,275
R01 · FY2000 · DK
CORE--HUMAN APPLICATIONS FACILITY$81,995
P30 · FY2000 · DK
PILOT AND FEASIBILITY PROGRAM$81,995
P30 · FY2000 · DK
P. AERUGINOSA COLONIZATION IN YOUNG CHILDREN WITH CYSTIC FIBROSIS$3,864
M01 · FY2000 · RR
P. AERUGINOSA COLONIZATION IN YOUNG CHILDREN WITH CYSTIC FIBROSIS$3,864
M01 · FY2000 · RR
MEASUREMENT OF TRANSEPITHELIAL ELECTRICAL POTENTIAL DIFFERENCES ACROS$3,864
M01 · FY2000 · RR
TRANSEPITHELIAL ELECTRICAL POTENTIAL DIFFERENCES ACROS$0
M01 · FY2000 · RR